TG Therapeutics (NASDAQ:TGTX) Announces Quarterly Earnings Results

TG Therapeutics (NASDAQ:TGTX - Get Free Report) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02), Briefing.com reports. The firm had revenue of $63.47 million for the quarter, compared to the consensus estimate of $54.60 million. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. The business's revenue was up 713.5% compared to the same quarter last year. During the same period last year, the company posted ($0.28) earnings per share.

TG Therapeutics Price Performance

TGTX stock traded up $0.54 during mid-day trading on Thursday, hitting $16.42. 8,477,473 shares of the stock were exchanged, compared to its average volume of 4,335,356. The stock has a market capitalization of $2.54 billion, a price-to-earnings ratio of 828.91 and a beta of 2.33. The business has a fifty day moving average price of $15.13 and a 200 day moving average price of $14.33. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.92 and a quick ratio of 5.18. TG Therapeutics has a 12 month low of $6.46 and a 12 month high of $35.67.

Insider Buying and Selling at TG Therapeutics

In other news, Director Laurence N. Charney sold 22,000 shares of the business's stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total transaction of $351,340.00. Following the transaction, the director now directly owns 215,229 shares of the company's stock, valued at $3,437,207.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 9.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on TGTX shares. HC Wainwright raised their price objective on TG Therapeutics from $45.00 to $49.00 and gave the company a "buy" rating in a research report on Thursday. JPMorgan Chase & Co. reissued an "overweight" rating and issued a $25.00 price objective on shares of TG Therapeutics in a report on Thursday, April 18th. B. Riley raised their price target on TG Therapeutics from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Monday, February 5th. The Goldman Sachs Group upped their price objective on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research report on Thursday, February 29th. Finally, StockNews.com lowered shares of TG Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, February 24th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, TG Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $29.83.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.